New research shows that an extract probiotic growing from the human microbiome could offer a drug-free topical therapy for patients with atopic dermatitis, and may protect against the action of pathogenic biofilms.
The researchers said that this therapy has worked, in terms of restoring the damaged skin barrier, equivalent to dexamethasone. Also the extract showed activity against pathogenic biofilms, and has anti-inflammatory effects.
Biofilms by Staphylococcus aureus – both methicillin-resistant (MRSA) that methicillin-susceptible (MSSA) – play an important role in patients with moderate and severe atopic dermatitis.
Therapies that can disturb these biofilms have huge potential to reduce not only the risk of infection, but to improve other aspects of the disease, since the bacterial colonization probably contributes to inflammation and breakage of the skin barrier.
Did not want to reveal the name of the probiotic because they are in the course of the copyrights, but has stated that it is a bacterium with the status of probiotic certified by the World Health Organization.
It is a purely physical process without chemicals to increase its activity.
In the studies presented, the extract has been used topically on normal skin samples taken from patients of plastic surgery.
When the extract topical probiotic was applied on the samples, the effect was similar to dexamethasone as it has restored the integrity of the skin barrier, measured with the impedance test of the skin, which is the ability of the skin to resist the electric current .
In addition, levels of the protein filaggrin – a critical component of the skin barrier – were twice as high in the skin treated with extract compared to untreated skin.
In the second study, the extract was tested for three probiotic properties antibiofilm: adherence, inhibition and detachment.
The non-stick property has doubled in the skin treated with the extract, compared to the one treated with the antibiotics vancomycin and meropenem.
These results suggest that the extract may treat and prevent MRSA biofilm in chronic skin diseases such as atopic dermatitis. Biofilm diseases are common.
They are the cause of almost all hospital-acquired infections and are associated with morbidity and mortality incredible.
Generally all antibiotics approved by the FDA so far have always been tested only in floating form, not clinging to any surface, and since both pathogenic microbes that live benign on the surface of the body preferentially in the form of biofilms. They live in communities protected from polymers produced by the extracellular microbial giving a tremendous defence against antibiotics.